Apellis Pharmaceuticals, Inc. (APLS) Tops Q3 EPS by 12c
Tweet
Share
E-mailGet Alerts APLS Hot Sheet
Join SI Premium – FREE
(Updated - October 30, 2025 8:17 AM EDT)
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q3 EPS of $1.67, $0.12 better than the analyst estimate of $1.55. Revenue for the quarter came in at $458.6 million versus the consensus estimate of $450.97 million.
For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
- Teleflex starts global pivotal trial for resorbable magnesium scaffold
- Fervo Energy (FRVO) PT Raised to $50 at Baird
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
